The AstraZeneca Coronavirus Jab is safe and should not be restricted in any population, the European Medicines Agency has insisted.
The European Medicines Agency (EMA) states that there is “no evidence” to stop using the sting.
Several European countries had suspended the introduction of the vaccine after fears about blood clots, and Germany stopped using vaccines under the age of 60 due to fears of an association with rare blood clots.
The controversial decision was made despite the EMA reviewing the safety data to ensure they are safe and that the benefits of the vaccine outweigh the risks.
EMA Executive Director Emercooke reaffirmed the safety of the vaccine today as the Agency’s Safety Committee reassembled to discuss the ongoing review of very rare cases of unusual blood clots associated with low platelet counts.
The Agency has not shown that the vaccine causes blood clots, but it is “possible” and further analysis of the underlying risk factors is ongoing.
It comes after Canada also announced it would stop rolling out the jab for those under 55.
The European countries that suspended the vaccine have been criticized as public polls showed a decline in confidence in the bite, even after authorities declared it safe.
UK drug regulators and the World Health Organization had urged Oxford / AstraZeneca to continue rolling out.
Chancellor Angela Merkel, 66, yesterday insisted that she would receive the AstraZeneca vaccine in person “when it is my turn”.
However, the German vaccine committee agreed that children under the age of 60 should only receive the bump if they belong to high-priority groups, including high-risk patients and medical staff.
The vaccine committee recommended “rare but very serious side effects” of blood clots “based on the available data”.
The UK has now delivered more than 30 million first-time vaccine doses with the Pfizer and AstraZeneca puffs.
The UK Medical and Health Products Regulatory Authority (MHRA) did not provide any evidence that the AstraZeneca sting caused blood clots in veins after a “rigorous” scientific review of all available data.
The EMA has announced that its review will identify all underlying risk factors for blood clots.
In its statement today it says: “At this stage the review has not identified any specific risk factors such as age, gender or a history of bleeding disorders for these very rare events.
“A causal link with the vaccine has not been established but it is possible and further analysis is ongoing.”
The EMA added, “As announced on March 18, the EMA believes that the benefits of the AstraZeneca vaccine in preventing Covid-19 with the associated risk of hospitalization and death outweigh the risks of side effects.”